Medical Information
Week ending August 22, 2026
1. This week’s recurring question themes
Product identity, formulation, and substitution — 3 questions/21 responses
- “Stromectol vs Heartgard—are these the same drug or different uses?”
- “What are the main ways brand and generic products are described differently?”
- “What’s the difference between ivermectin used orally in tablets and…topically in creams?” Responses generally distinguish human versus veterinary products, active ingredient, route, labeling, and formulation. However, answers vary between calling products “different drugs” and “the same active ingredient,” indicating a need for precise MI wording.
Comparative and positioning questions — 2 questions/14 responses
- Ivermectin versus albendazole for intestinal worms.
- Ivermectin alongside doxycycline and whether comparisons reflect evidence or promotional framing.
These answers are relatively substantive, but focus on comparative interpretation rather than a defined product-information question. They should be monitored for FAQ development rather than treated as a primary SRD gap this week.
Dosing and administration — 2 questions/14 responses
- Adult ivermectin use and dose schedule for scabies.
- Strongyloidiasis dosing in a 70-year-old.
Both are direct HCP/patient MI questions and repeatedly contain dosing-specific content. The PI group averaged 349 words, suggesting reasonably detailed answers, but not necessarily consistent or label-aligned answers.
Special populations, contraindications, and adverse reactions — 3 questions/21 responses
- Contraindications and when ivermectin should be avoided.
- Serious adverse reactions and when to stop treatment or seek care.
- Age-related dosing in an older adult.
Pregnancy/lactation, pediatric, renal, allergy, and interaction-related qualifiers appear frequently, but inconsistently.
2. Where no consistent answer currently exists
The clearest MI gap is the question: “Can ivermectin be used for scabies, and what dose schedule is recommended for adults?” Five answer variants mention contraindication-related content, while two omit it; only one mentions infection-risk considerations. A person asking this today may therefore receive materially different completeness depending on the assistant used.
The older-adult strongyloidiasis question also lacks a uniform answer. Variants disagree on whether to mention renal considerations, infection-risk context, contraindications, and pregnancy/lactation caveats. Although the core response—no adjustment solely for age—is repeated, the surrounding qualification is not standardized.
Other inconsistency flags affect COVID-19 labeling/off-label use, general contraindications, adverse reactions, oral/topical use, and brand/generic descriptions. Overall, there were 17 inconsistency flags across 10 questions and 70 responses.
3. Off-label and substitution questions
Off-label content appears in 17 responses, concentrated in scabies, COVID-19, human/veterinary product distinctions, and formulation questions. COVID-19 answers are comparatively consistent in stating that prescribing information does not support treatment, although the contraindication category is inconsistently included. Scabies responses identify oral ivermectin as an alternative or adjunct in some settings, but the inconsistent safety qualifiers suggest the existing SRD should be reviewed for completeness and jurisdiction-specific labeling.
Generic/substitution content appears in 10 responses and is generally handled thoroughly: answers distinguish proprietary versus nonproprietary naming, inactive ingredients, formulation, strength, and labeling. However, statements such as generics “behave the same in the body” should be checked against approved-label language. Compounded products appear only once, in the oral/topical question, suggesting this MI theme is not well represented in surfaced content and may warrant a targeted FAQ if received in direct inquiries.
4. Trend across weeks
This is a baseline week: no previous-week comparison is available and the trend history contains only 2026-08-22. No recurring or growing pattern can therefore be established. The 10 questions should be used as the initial prioritization set.
5. Recommended actions
- Create or update an SRD for oral ivermectin in scabies, covering adult administration, repeat-dose language, formulation/label status, and consistent special-population qualifiers. Highest priority: 7 responses plus two inconsistency categories.
- Create/update an SRD for strongyloidiasis in older adults, clearly separating age-based dosing from renal/hepatic function, interactions, and complicated infection scenarios. Seven responses and four inconsistency categories support action.
- Review the contraindications and serious-adverse-reaction SRDs for currency and consistent scope, including allergy, pediatric/weight restrictions, pregnancy/lactation, neurologic symptoms, and escalation instructions.
- Update a product identity/substitution FAQ covering Stromectol versus Heartgard, human versus veterinary products, brand/generic distinctions, and oral versus topical formulations.
- Monitor albendazole/doxycycline comparison questions; no new SRD is warranted yet, but consider a concise, non-promotional comparative FAQ if this baseline topic recurs.